Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376: 1211-1222.
Published: 26th April 2017
Authors: Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Bayer-Westendorf J, Bounameaux H et al.
Some 3396 patients who completed their initial anticoagulation were randomized to aspirin or rivaroxaban for a further twelve months. Recurrent symptomatic venous thromboembolism was more common in patients on aspirin: 4.4 versus 1.5 per cent on 20mg and 1.2 per cent on 10mg rivaroxaban (P<0.001 for both doses). Major bleeding rates were similar.Pubmed Link
You may also be interested in
Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382: 1599-1607
Authors: Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM et al.
Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. N Engl J Med 2019; 380: 1305-1315.
Authors: Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS et al.
Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: Systematic review and meta-analysis of randomized clinical trials. Surgery 2018; 164: 1234-1240.
Authors: Rausa E, Kelly ME, Asti E, Aiolfi A, Bonitta G, Winter DC et al.
Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380: 720-728.
Authors: Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al.
Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380: 711-719.
Authors: Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al.
Thromboembolism incidence and prophylaxis use after gastrectomy among Korean patients with gastric adenocarcinoma. The PROTECTOR randomized clinical trial. JAMA Surg 2018; 153: 939-946.
Authors: Jung YJ, Seo HS, Park CH, Jeon HM, Kim J-I, Yim HW et al.
Venous thromboembolism incidence and prophylaxis use after gastrectomy among Korean patients with gastric adenocarcinoma. The PROTECTOR randomized clinical trial. JAMA Surg 2018; 153: 939-946.
Authors: Jung YJ, Seo HS, Park CY, Jeon HM, Kim J-I, Yim HW et al.
Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol 2018; 1: e25-e33.
Authors: Ten Cate-Hoek AJ, Amin EE, Bouman AC, Meijer K, Tick LW, Middeldorp S et al.
Randomized double-blinded study comparing medical treatment versus iliac vein stenting in chronic venous disease. J Vasc Surg Venous Lymphatic 2018; 6: 183-191.
Authors: Rossi FH, Kambara AM, Izukawa NM, Rodrugues TO, Rossi CB, Sousa AG et al.
Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615-624.
Authors: Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al.
Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377: 2240-2252.
Authors: Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ et al.
Timing of chemical thromboprophylaxis and deep vein thrombosis in major colorectal surgery: a randomized clinical trial. Ann Surg 2016; 264: 632-639.
Authors: Zaghiyan KN, Sax HC, Miraflor E, Crossman D, Wagner W, Mirocha J et al.